These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26787617)

  • 1. Case report: severe cytomegalovirus primary infection in an immunocompetent adult with disseminated intravascular coagulation treated with valganciclovir.
    Müller NF; Schampera M; Jahn G; Malek NP; Berg CP; Hamprecht K
    BMC Infect Dis; 2016 Jan; 16():19. PubMed ID: 26787617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated intravascular coagulation due to cytomegalovirus infection in an immunocompetent adult treated with plasma exchange.
    Niewold TB; Bundrick JB
    Am J Hematol; 2006 Jun; 81(6):454-7. PubMed ID: 16680750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
    Humar A; Siegal D; Moussa G; Kumar D
    J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review.
    Lee CY; Chen YH; Lu PL
    BMC Infect Dis; 2017 Feb; 17(1):113. PubMed ID: 28143418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus pneumonia in immunocompetent host: case report and literature review.
    Grilli E; Galati V; Bordi L; Taglietti F; Petrosillo N
    J Clin Virol; 2012 Dec; 55(4):356-9. PubMed ID: 22975082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir.
    Subramanian V; Finlayson C; Harrison T; Rice P; Pollok R
    J Crohns Colitis; 2010 Jun; 4(2):199-202. PubMed ID: 21122506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
    Baradhi KM; Aure RL; El-Amm JM
    Transplant Proc; 2018; 50(1):142-144. PubMed ID: 29407298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir.
    Fernández-Ruiz M; Muñoz-Codoceo C; López-Medrano F; Faré-García R; Carbonell-Porras A; Garfia-Castillo C; Muñoz-Gómez R; Aguado-García JM
    Intern Med; 2008; 47(22):1963-6. PubMed ID: 19015608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
    Grossi P; Mohacsi P; Szabolcs Z; Potena L
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
    Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
    Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with oral valganciclovir of primary CMV enterocolitis in a congenitally infected infant.
    Irizarry K; Honigbaum S; Demmler-Harrison G; Rippel S; Wilsey M
    Fetal Pediatr Pathol; 2011; 30(6):437-41. PubMed ID: 21905765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.